Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt

JP Sevillaa Life Sciences Group, Data for Decisions LLC, Waltham, MA, USA;b Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USAView further author information

Daria Burnesa Life Sciences Group, Data for Decisions LLC, Waltham, MA, USACorrespondence[email protected]

https://orcid.org/0000-0002-8624-1344 View further author information

Rehab Zakaria El Saiec Medical Department, Pfizer, Cairo, EgyptView further author information

Hammam Haridyd Medical & Scientific Affairs EM-AfME, Pfizer Gulf, Dubai, United Arab EmiratesView further author information

Matt Wassermane Health Economics and Outcomes Research, Pfizer Inc, New York City, NY, USAView further author information

Sarah Pughf Medical and Scientific Affairs, Pfizer Inc, Collegeville, PA, USAView further author information

Johnna Perdrizete Health Economics and Outcomes Research, Pfizer Inc, New York City, NY, USAView further author information

David Blooma Life Sciences Group, Data for Decisions LLC, Waltham, MA, USA;b Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USAView further author information

show all

Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt

Supplemental Material

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt

Supplemental Material

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date